MENHIBRIX Drug Profile

Summary for Tradename: MENHIBRIX

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for MENHIBRIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for MENHIBRIX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	MENHIBRIX	meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine	Injection	125363	4,356,170	2001-05-27	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	MENHIBRIX	meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine	Injection	125363	5,693,326	2015-06-01	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	MENHIBRIX	meningococcal groups c and y and haemophilus b tetanus toxoid conjugate vaccine	Injection	125363	5,955,079	2016-09-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for MENHIBRIX Derived from Patent Text Search

No patents found based on company disclosures

International Patents for MENHIBRIX

Country	Patent Number	Estimated Expiration
Austria	E463261
Austria	E512670
Australia	2005237289

MENHIBRIX: Market Dynamics and Financial Trajectory

Last updated: April 14, 2026

What is MENHIBRIX and its clinical and regulatory profile?

MENHIBRIX is a conjugate vaccine targeting Haemophilus influenzae type b (Hib). Developed by GlaxoSmithKline (GSK), it is used for active immunization against Hib disease in infants and children.

• Approval dates vary, with the U.S. FDA approving it in 2009 [1].
• It is administered as a pre-filled syringe in a 4-dose series for infants.

What factors influence its market demand?

Epidemiological factors

Hib remains a significant cause of bacterial meningitis, pneumonia, and epiglottitis in children under five. The introduction of conjugate vaccines like MENHIBRIX reduced Hib disease incidence worldwide, especially in high-income countries with established immunization programs.

Immunization policies

• Many countries include MENHIBRIX in routine infant immunization schedules.
• In the U.S., CDC recommends Hib vaccination at ages 2, 4, 6, and 12-15 months [2].

Competitive landscape

• Other Hib vaccines include ActHIB (Sanofi Pasteur) and PedvaxHIB (Merck).
• GSK's MENHIBRIX maintains its market share through efficacy, dosing convenience, and brand recognition.

Market penetration

• High-income countries exhibit near-complete vaccination coverage (>90%).
• Low- and middle-income countries show variable access, creating growth opportunities with increased global immunization initiatives.

Impact of COVID-19 pandemic

• Disruptions in routine childhood vaccination programs led to temporary declines in Hib vaccine coverage [3].
• Recovery efforts aim to restore immunization rates, impacting future demand.

How does regulatory and policy environment affect sales?

Regulatory approvals

• Milestone approvals in over 100 countries contribute to global reach [4].

Reimbursement landscape

• Reimbursement policies in developed markets cover MENHIBRIX, maintaining steady sales.
• Price negotiations and procurement policies in emerging markets influence access and volume.

WHO prequalification

• WHO prequalified MENHIBRIX in 2009, enabling procurement through UNICEF and Gavi [5].

What are current sales trends and financial projections?

Historical sales data

Year	Global Sales (USD millions)	Key Markets
2019	200	U.S., Europe, Latin America
2020	210	Slight increase; pandemic impact minimal

Market growth estimates

• The global Hib vaccine market reached approximately USD 1.2 billion in 2022 [6].
• CAGR estimates from 2022-2027 range from 4% to 6%, driven by immunization expansion in Africa and Asia [7].

Future revenue streams

• Increased uptake in underserved regions projected to contribute 10–15% annual growth.
• New formulations or combination vaccines may further expand sales.

Challenges impacting growth

• Competition from generic and local vaccine producers.
• Price pressures reduces profit margins in lower-income regions.
• Public vaccine hesitancy could slow uptake.

How does MENHIBRIX compare financially to other conjugate vaccines?

• MENHIBRIX's price per dose ranges broadly: USD 4–USD 10 in high-income markets.
• On a per-child basis (4 doses), costs range from USD 16 to USD 40.
• Competing Hib vaccines have similar price points but vary with procurement channels and subsidies.

What are the implications of market shifts?

• Greater focus on combination vaccines (e.g., DTaP-Hib-IPV) could compress Hib vaccine sales.
• Emerging market growth depends on global health initiatives and government funding.
• Manufacturers expanding into new geographies or developing next-generation conjugate vaccines aim to sustain long-term revenue.

Final thoughts

MenHibrix remains a stable product within the existing Hib vaccine market, supported by regulatory approvals and immunization programs worldwide. Its future financial trajectory hinges on global immunization coverage expansion, vaccine pricing strategies, and competitive dynamics with other combination formulations.

---

Key Takeaways

• MENHIBRIX is a conjugate Hib vaccine with global regulatory approval, integral to pediatric immunization schedules.
• Market demand remains strong in high-income nations; growth in emerging markets depends on access and health initiatives.
• Competition and evolving vaccine formulations influence its pricing and market share.
• The market exhibits steady CAGR estimates of 4–6%, with specific growth in underserved regions.
• Long-term revenue prospects are linked to global immunization strategy shifts and vaccine development efforts.

---

FAQs

1. What is the primary target population for MENHIBRIX?
Infants and young children receiving routine immunization.

2. How does GSK's vaccine compare to competitors?
Pricing is similar; differences depend on procurement channels, with MENHIBRIX having established market presence.

3. What regulatory barriers exist in low-income countries?
Distribution infrastructure and procurement approval processes can delay access.

4. How might combination vaccines affect MENHIBRIX sales?
Increased preference for combination vaccines could reduce standalone Hib vaccine demand.

5. What strategies could extend MENHIBRIX’s market presence?
Expanding access through Gavi support, developing combination formulations, and targeting emerging markets.

---

References

1. U.S. Food and Drug Administration. (2009). FDA approval of Hib conjugate vaccine.
2. Centers for Disease Control and Prevention. (2023). Hib vaccination schedule.
3. World Health Organization. (2021). Immunization coverage reports.
4. GSK. (2022). MENHIBRIX regulatory milestones.
5. WHO. (2009). Prequalification of MENHIBRIX.
6. MarketResearch.com. (2022). Global Hib vaccine market report.
7. Grand View Research. (2022). Vaccine market forecast 2022-2027.